Avecho Biotechnology Limited (ASX:AVE)

Market Cap	22.21M
Revenue (ttm)	1.38M
Net Income (ttm)	-3.62M
Shares Out	3.17B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,408,011
Average Volume	3,455,958
Open	0.0070
Previous Close	0.0070
Day's Range	0.0070 - 0.0070
52-Week Range	0.0010 - 0.0090
Beta	1.09
RSI	54.51
Earnings Date	Nov 28, 2025

About Avecho Biotechnology

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its human health portfolio covers delivery of pharmaceutical products for pain and dermatology applications through gels, injectables, and patches. In additio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVE

Financial Performance

In 2024, Avecho Biotechnology's revenue was 1.13 million, an increase of 139.19% compared to the previous year's 473,551. Losses were -3.12 million, -9.15% less than in 2023.